Literature DB >> 14744921

Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.

Munavvar Izhar1, Tunji Alausa, Amy Folker, Elena Hung, George L Bakris.   

Abstract

Cyclo-oxygenase (COX) inhibitors attenuate the antihypertensive effects of angiotensin-converting enzyme (ACE) inhibitors and reduce kidney function. The study tests the hypothesis that these two classes of drugs have similar effects on glomerular filtration rate (GFR) and 24-hour blood pressure. The primary endpoint was change in 24-hour systolic blood pressure. Using a randomized crossover design, 25 black and Hispanic hypertensive participants (mean age 58+/-3 years) with osteoarthritis were studied. All participants received an ACE inhibitor at baseline. Once systolic blood pressure was <140 mm Hg, either celecoxib 200 mg/d or diclofenac 75 mg twice daily for 4 weeks was started. After measurements were obtained, all participants underwent a 2-week washout period and crossed over to the other drug for 4 weeks. A significant difference in mean 24-hour systolic blood pressure was noted between groups at 4 weeks (+4.1+/-1.1 mm Hg diclofenac versus +0.6+/-0.6 mm Hg celecoxib; P=0.01). However, because celecoxib has duration of action shorter than 24 hours, we compared ambulatory values at celecoxib trough and peak activities. At peak, no difference in systolic blood pressure was noted between agents (+3.6+/-0.04 mm Hg diclofenac versus +4.2+/-1.9 mm Hg celecoxib; P=0.67). GFR was also differentially affected at 24 hours (-9.9+/-2.4 mL/min diclofenac versus -0.4+/-1.2 mL/min celecoxib; P=0.01). We conclude that diclofenac and celecoxib increase systolic blood pressure at peak levels; however, these agents differ in their 24-hour effects. Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744921     DOI: 10.1161/01.HYP.0000115921.55353.e0

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  17 in total

1.  Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1.

Authors:  Dong-juan Zhang; Li-hong Chen; Ya-hua Zhang; Guang-rui Yang; Dou Dou; Yuan-sheng Gao; Xiao-yan Zhang; Xiao-mu Kong; Pan Zhao; Dan Pu; Ming-fen Wei; Matthew-D Breyer; You-fei Guan
Journal:  Acta Pharmacol Sin       Date:  2010-09-27       Impact factor: 6.150

Review 2.  A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects.

Authors:  Emma J Turtle; James W Dear; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

Review 3.  Cardiovascular risk, hypertension, and NSAIDs.

Authors:  William B White
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

4.  Blood pressure destabilization on nonsteroidal antiinflammatory agents: acetaminophen exposed?

Authors:  William B White; Patrick Campbell
Journal:  Circulation       Date:  2010-10-18       Impact factor: 29.690

5.  Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II.

Authors:  Torrance Green; Jorge Rodriguez; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

6.  Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting.

Authors:  Youfei Guan; Yahua Zhang; Jing Wu; Zhonghua Qi; Guangrui Yang; Dou Dou; Yuansheng Gao; Lihong Chen; Xiaoyan Zhang; Linda S Davis; Mingfeng Wei; Xuefeng Fan; Monica Carmosino; Chuanming Hao; John D Imig; Richard M Breyer; Matthew D Breyer
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

Review 8.  Secondary hypertension: interfering substances.

Authors:  Ehud Grossman; Franz H Messerli
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-07       Impact factor: 3.738

9.  Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.

Authors:  Frank Ruschitzka; Jeffrey S Borer; Henry Krum; Andreas J Flammer; Neville D Yeomans; Peter Libby; Thomas F Lüscher; Daniel H Solomon; M Elaine Husni; David Y Graham; Deborah A Davey; Lisa M Wisniewski; Venu Menon; Rana Fayyad; Bruce Beckerman; Dinu Iorga; A Michael Lincoff; Steven E Nissen
Journal:  Eur Heart J       Date:  2017-11-21       Impact factor: 29.983

10.  Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.

Authors:  Hisham Aljadhey; Wanzhu Tu; Richard A Hansen; Susan J Blalock; D Craig Brater; Michael D Murray
Journal:  BMC Cardiovasc Disord       Date:  2012-10-24       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.